Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
The system “I can hear, but I can’t understand” proved to be an easy-to-use and effective tool to telemonitor hearing aid users.
Why it matters
This study developed and tested an internet-based system to guide and remotely monitor hearing aid users, finding improved performance and increased hearing aid use. Participants had no evidence of cognitive impairment, and the study does not test any treatment, cure, or prevention for Alzheimer's disease.
-
29/100
Dietary diversity is one of the diet quality.
Why it matters
This review notes that poor dietary diversity is associated with cognitive impairment and discusses food-based and non-food-based interventions to improve diet. It does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Medicare enrollment among people with Alzheimer’s Disease and Related Dementias (ADRD) has reached an all-time high with about 12% of beneficiaries having an ADRD diagnosis.
Why it matters
Among fee-for-service Medicare beneficiaries with an ADRD diagnosis, race/ethnicity and dual Medicare-Medicaid eligibility were the strongest predictors of disenrollment, with African American beneficiaries disenrolling at 7.9% versus 4.3% among White beneficiaries. This is about insurance enrollment patterns, not about treating, curing or preventing Alzheimer's disease.
-
From April-December 2020, 279 PAs were submitted via NLX and 83% were automatically approved in real-time.
Why it matters
This study of a prior authorization tool in a Medicare Advantage lung cancer population found that 83% of requests were automatically approved and that guideline-concordant patients had lower total cost of care. It contains no research findings on treating, curing, or preventing Alzheimer's disease.
-
Future direction of this work focuses on system wide improvements to promote multi-organisational interdisciplinary healthcare and social services professionals work in care homes.
Why it matters
This paper describes a Buckinghamshire programme in which pharmacists, technicians and geriatricians reviewed medications for care home residents, stopping 2134 medications and resolving 942 safety issues. It addresses medicines safety and polypharmacy in care homes, not the treatment, cure or prevention of Alzheimer's disease.
-
29/100
Overall, the pathway to diagnosis (i.e., time from signs/symptoms recognition to diagnosis) ranged from 2 to 15 years.
Why it matters
This study describes how long it took people with dementia to receive a diagnosis and how many specialists they saw in different regions. It is about the diagnostic pathway, not about treating, curing or preventing Alzheimer's disease.
-
Overall health is significantly impacted by where one lives.
Why it matters
In 100 African American participants, the relationship between neighborhood disadvantage and cognitive test scores was not statistically significant except for one test of digit span. The finding that participants with dementia tended to live in more disadvantaged areas was only a trend, so no firm conclusion can be drawn.
-
Across New England stakeholders are promoting healthy aging by building age-friendly communities (healthyagingdatareports.org).
Why it matters
This project created community-level data reports on healthy aging across New England, including rates of Alzheimer's disease or related dementias among adults 65 and older. It provides local information that could help communities target health disparities, but it does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Risk of Alzheimer disease is increased in patients with diabetes.
Why it matters
This paper identifies insulin resistance as a mechanism of impaired cognitive dysfunction and notes that risk of Alzheimer disease is increased in patients with diabetes. It describes how amyloid beta oligomers impair insulin signaling and how attenuation of the PI-3 kinase pathway is involved in tau hyperphosphorylation.
-
MemoryCare, in its 13th year of operation in Asheville, NC, is an independent, non-profit organization dedicated to providing medical care to older adults with cognitive impairment inclusive of a case management component that provides support and education to their families and caregivers.
Why it matters
This is a descriptive report of a nonprofit dementia care program that provided medical care, case management, and caregiver support, with most caregivers reporting improved knowledge of memory disorders. It describes a care model and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
A 79-year-old woman is referred by her primary care physician for an evaluation regarding a possible psychiatric diagnosis.
Why it matters
This case report describes a 79-year-old woman with four months of increasing confusion, forgetfulness, insomnia, irritability, reduced appetite and weight loss, referred for evaluation of a possible psychiatric diagnosis. It is a single case and does not provide evidence about treating, curing or preventing Alzheimer's disease.
-
Analysis of the use of hypnotic medication versus CBT for insomnia using an established model for ethical medical decision making leads to the conclusion that hypnotics are not appropriate as the initial treatment in cases of chronic insomnia.
Why it matters
This article argues that hypnotic medications should not be used as initial treatment for chronic insomnia, favoring cognitive behavioral therapy instead. It mentions cognitive impairment as a side effect of hypnotics but does not study Alzheimer's disease treatment, cure or prevention.
-
Despite frequent neuropathological findings, the prevalence of dementia in people with Down syndrome is thought to be no higher than in the general population.
Why it matters
This review notes that dementia prevalence in people with Down syndrome is thought to be no higher than in the general population, though onset is about two decades earlier. It recommends that doctors first rule out other medical problems that can mimic Alzheimer's disease when a person with Down syndrome declines in function.
-
29/100
Through deinstitutionalization, more adults with mental retardation are living in the community under the care of family physicians.
Why it matters
This case report describes a 43-year-old woman with Down syndrome whose decline over three years was attributed to Alzheimer-type dementia. It provides no treatment or prevention findings.
-
Down syndrome (DS) subjects develop Alzheimer disease (AD) histopathology before they develop dementia.
Why it matters
This EEG study found that adults with Down syndrome who did not have dementia already showed brain wave patterns similar to those seen in Alzheimer's patients. The authors suggest these abnormalities are probably due to Alzheimer's brain changes, but the study did not test any treatment.
-
The Wingham Assessment and Rehabilitation Unit is part of the Manning Valley Area Health Service in New England, New South Wales.
Why it matters
This paper describes a model in country New South Wales for managing people diagnosed with dementia in the community for as long as possible. It notes a deficit of nursing home and hostel places in the area, based on 1988 figures.
-
28/100
Canada’s Drug Agency (CDA-AMC) recommends that Leqembi be reimbursed by public drug plans for the treatment of adult patients in the early stages of Alzheimer disease (AD) (i.e., mild cognitive impairment [MCI] or mild dementia) who have evidence of amyloid in the brain and who are APOE epsilon 4 (APOE4) noncarriers or heterozygotes, if certain conditions are met.
Why it matters
Canada's Drug Agency recommends public reimbursement of Leqembi only for adults 50 or older in the early stages of Alzheimer disease with confirmed amyloid who are APOE4 noncarriers or heterozygotes, and only if certain conditions are met. Treatment should not be started or continued in patients unable or unwilling to undergo the recommended MRI monitoring for ARIAs, and should not be reimbursed in combination with other monoclonal antibody therapies for Alzheimer disease or after progression to moderate dementia.
-
At present, there is no cure for dementia.
Why it matters
This review states that there is currently no cure for dementia, while reporting that multidomain interventions showed promising beneficial effects on cognitive performance, since small changes across multiple risk factors can combine favorably. It notes that identifying higher-risk individuals may allow strategies to prevent or delay dementia onset, and that longer follow-up is needed.
-
Glyphosate is widely used in the United States (US) agriculture, particularly in regions with intensive crop production.
Why it matters
This county-level study found higher three-year lagged glyphosate use was associated with increased heart disease mortality, but no significant associations were observed for the other chronic disease outcomes, including Alzheimer's disease. It reports no significant link to Alzheimer's disease and does not test any treatment, cure, or prevention.
-
La carta al editor presenta recomendaciones actualizadas para el uso de donanemab en la enfermedad de Alzheimer (EA), basadas en su papel dentro de la hipótesis de la cascada amiloide.
Why it matters
These recommendations state that donanemab is indicated only for patients with mild cognitive impairment or mild dementia, not advanced stages, and that biomarkers are needed to confirm amyloid pathology and select candidates. They highlight ARIA as a safety concern with higher incidence in treated patients, particularly APOE ε4 homozygotes, requiring genetic screening and MRI monitoring.
-
Cognitive training shows potential in preventing cognitive decline in individuals at risk for Alzheimer's disease, especially as part of multimodal interventions, though current evidence varies in quality and clarity.
Why it matters
This review reports that cognitive training shows potential in preventing cognitive decline in people at risk for Alzheimer's disease, especially as part of multimodal interventions. However, it states that current evidence varies in quality and clarity, so no firm conclusion about prevention can be drawn.
-
Cognitive training appears effective in improving cognitive functions and delaying cognitive decline in people at risk of Alzheimer's disease but requires more standardized research for conclusive evidence.
Why it matters
This review reports that cognitive training appears effective in improving cognitive functions and delaying cognitive decline in people at risk of Alzheimer's disease. It states that more standardized research is required for conclusive evidence, so the effect is not yet firmly established.
-
28/100
Alzheimer's Disease (AD) is a progressive neurodegenerative condition that gradually impairs cognitive abilities such as memory, attention, and problem-solving, leading to significant challenges in everyday functioning and a decline in quality of life.
Why it matters
This paper discusses cognitive training as a complement to conventional treatments for Alzheimer's disease, focusing on neuroplasticity and cognitive performance. It does not present new trial evidence that cognitive training prevents or cures the disease.
-
Providing end-of-life care for patients with COPD, dementia, and cancer involves a focus on symptom management, integration of palliative care, and respecting patient preferences, while engaging families in the care process.
Why it matters
This review says end-of-life care for patients with coexisting COPD, dementia, and cancer involves symptom management, palliative care integration, respecting patient preferences, and engaging families. It notes that variability in practice and systemic challenges remain significant barriers to optimal care.
-
Overall, AI has substantial potential to support more precise, person-centred care for older adults, but realising this promise will require multimorbidity-aware, transparent models, robust evaluation in diverse geriatric populations and governance frameworks that ensure fairness, privacy and meaningful human oversight.
Why it matters
This review states that artificial intelligence has substantial potential to support more precise, person-centred care for older adults, but realising this promise requires multimorbidity-aware, transparent models, robust evaluation in diverse geriatric populations, and governance frameworks. It does not report findings on treating, curing, or preventing Alzheimer's disease.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Rural depopulation and the rural‐urban gap in cognitive functioning among older adults
- Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research
- Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective
- A comparison of clinical features in early- and late-onset primary degenerative dementia. One entity or two?
- The prevalence of dementia in older people in an urban population of Korea: the Seoul study
- Home-based, caregiver-assisted multimodal exercise and cognitive training via videoconferencing for older adults with mild dementia: A mixed-methods pilot study
- Slowing gait and risk for cognitive impairment: The hippocampus as a shared neural substrate
- The Silent Crisis: Loneliness in Older Adults-A Critical Review of Impacts, Strategies and Path Forward
- The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial
- Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis